This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Reasons Why Ironwood Stock Should Be in Your Portfolio
by Zacks Equity Research
We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.
MEI Pharma (MEIP) Catches Eye: Stock Jumps 8.1%
by Zacks Equity Research
MEI Pharma (MEIP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Are You Looking for a Top Momentum Pick? Why Ironwood Pharmaceuticals (IRWD) is a Great Choice
by Zacks Equity Research
Does Ironwood Pharmaceuticals (IRWD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) shares rose nearly 8% in the last trading session, amid huge volumes.
Is Ironwood Pharmaceuticals (IRWD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IRWD) Outperforming Other Medical Stocks This Year?
Moving Average Crossover Alert: Ironwood Pharmaceuticals
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Pacira's Late-Stage Study on Exparel Label Expansion Positive
by Zacks Equity Research
Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M
by Zacks Equity Research
Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.
Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher
by Zacks Equity Research
Sage Therapeutics (SAGE) shares rose more than 7% in the last trading session, amid huge volumes.
Top Ranked Momentum Stocks to Buy for December 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd
Catalyst Focuses on Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst (CPRX) focuses on the development of Firdapse for additional indications.
The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics
5 Best-Performing, Top-Ranked Growth Stocks of November
by Nalak Das
Wall Street's impressive bull run is likely to continue in the near term. At this stage, it will be prudent to invest in growth stocks with a favorable Zacks Rank.
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD
by Sweta Killa
Healthcare bounced back with an outperformance starting the fourth quarter.
Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10%
by Zacks Equity Research
Esperion Therapeutics (ESPR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
FibroGen (FGEN) Soars: Stock Adds 9.6% in Session
by Zacks Equity Research
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Ironwood Pharmaceuticals, Inc. (IRWD) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Ironwood Pharmaceuticals, Inc. (IRWD).
Pharma Sector Tops in October: Best ETFs & Stocks
by Sanghamitra Saha
Pharma sector wins in October, making these ETFs and stocks winners.
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.
Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock
by Zacks Equity Research
Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 300.00% and 36.62%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?